2013 Apr 15 Annual Report 2012 - Phosphagenics

More documents

Recommendations

Info

Independent Auditor’s Report 112 PHOSPHAGENICS ANNUAL REPORT 2012
Additional Shareholder Information Additional Shareholder Information-ASX Listing Rule 4.10. as at 1 April 2013 SHARES : Twenty Largest Holdings : Ordinary Fully Paid Shares. As at 1/04/13 % Issued Shares Ranking CITICORP NOMINEES PTY LIMITED 112,475,798 11.02 1 NATIONAL NOMINEES LIMITED 77,655,717 7.61 2 J P MORGAN NOMINEES AUSTRALIA LIMITED 69,287,125 6.79 3 PAROHA NOMINEES PTY LTD 61,167,143 6.00 4 JOGRA NOMINEES PTY LTD 45,684,658 4.48 5 MR ROSS COPELAND + MRS GINA COPELAND 43,887,735 4.30 6 MERRILL LYNCH (AUSTRALIA) NOMINEES PTY LIMITED 39,383,376 3.86 7 HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED 24,032,367 2.36 8 JP MORGAN NOMINEES AUSTRALIA LIMITED 16,197,463 1.59 9 ZAHAVETTE PTY LTD 13,737,372 1.35 10 MR ROSS GRAHAM COPELAND + MRS GINA COPELAND 10,854,793 1.06 11 SUPERDES PTY LTD 8,000,000 0.78 12 MR JEFFREY MARKOFF 7,365,575 0.72 13 DALSEY PTY LTD 6,448,752 0.63 14 PARADYCE PTY LTD 6,172,552 0.61 15 MR DAVID SEGAL 6,113,666 0.60 16 DR ESRA OGRU 5,711,610 0.56 17 BNP PARIBAS NOMS PTY LTD 5,625,000 0.55 18 DECOLAND HOLDINGS PTY LTD 5,500,000 0.54 19 MRS DANIELLE SEGAL 5,140,000 0.50 20 Sub-Total – Top 20 Holders 570,440,702 55.91 – Other Holders 449,775,255.00 44.09 TOTAL ISSUED SHARES 1,020,215,957 100.00 113 VOTING RIGHTS – Shares : One vote per share. RANGE OF SHAREHOLDERS 1/04/13 Range Holders Units % 1-1000 469 120,599 0.01 1001-5000 1,104 3,488,240 0.34 5001-10000 929 7,511,125 0.74 10001-100000 2,764 105,065,932 10.30 100001-OVER 886 904,030,061 88.61 6,152 1,020,215,957 100.00 MARKETABLE PARCELS - SHARES Holdings that are less than a marketable parcel of the Company’s ordinary fully paid shares as at 1 April 2013 at a closing price of A$0.13 a share, consisted of a total of 1,148 holders each holding a parcel of less than 3,847 shares and covering an aggregate of 1,678,286 shares. ADDITIONAL SHAREHOLDER INFORMATION
Page 1 and 2:
20 12 Annual Report PHOSPHAGENICS P
Page 3 and 4:
highlights March... April... May...
Page 5 and 6:
03 Jonathan Addison Chairman & Inde
Page 7 and 8:
COLLABORATIONS Strategic Collaborat
Page 9 and 10:
The Phosphagenics Evolution THE STO
Page 11 and 12:
“ We also reached agreement with
Page 13 and 14:
Overview of our opioid development
Page 15 and 16:
13 is branded as Butrans or Norspan
Page 17 and 18:
Personal Care ASHLAND INC (FORMERLY
Page 19 and 20:
BEAUTY IS MORE THAN SKIN DEEP 17 EL
Page 21 and 22:
cellulite contour crème BioElixia
Page 23 and 24:
Intellectual Property Title Countri
Page 25 and 26:
2009 2008 2007 2006 6.8 7.8 22.2 23
Page 27 and 28:
DR ESRA OGRU (AGED 37 YEARS) BSC (H
Page 29 and 30:
Senior Management DR PAUL GAVIN Chi
Page 31 and 32:
Phosphagenics Limited ABN 32 056 48
Page 33 and 34:
Directors’ Report Your directors
Page 35 and 36:
Directors’ Report continued Looki
Page 37 and 38:
Directors’ Report continued Commi
Page 39 and 40:
Directors’ Report continued REMUN
Page 41 and 42:
Page 43 and 44:
Directors’ Report continued Share
Page 45 and 46:
Directors’ Report continued Share
Page 47 and 48:
Exercise Price Expiry Date Net othe
Page 49 and 50:
Exercise Price Expiry Date Net othe
Page 51 and 52:
Fair value per performance right at
Page 53 and 54:
Page 55 and 56:
Auditors Independence Declaration 5
Page 57 and 58:
Corporate Governance Statement cont
Page 59 and 60:
Page 61 and 62:
Page 63 and 64: Corporate Governance Statement cont
Page 65 and 66: Corporate Governance Statement cont
Page 67 and 68: Consolidated statement of fi nancia
Page 69 and 70: Consolidated statement of changes i
Page 71 and 72: Notes to the consolidated fi nancia
Page 73 and 74: Application date of standard Impact
Page 113: Independent Auditor’s Report 111
Page 117 and 118: Additional Shareholder Information
Page 119: corporate directory Phosphagenics L
show all

2013 Apr 15 Annual Report 2012 - Phosphagenics

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?